Company Overview
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Why Investors Should Care
Net profit has compounded at 31.8% per year over the last five years.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR 31.8%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | 31.82% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +210.23% |
| 6 Months: | -11.57% |
| 3 Months: | +8.00% |
| 1 Month: | -8.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 31.8% over 5 years.
CONS
- Trading 52.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APLM Apollomics, Inc. | 17.28 | -2.28 | $37.95M | 0.00% | - | - | - | 31.82% |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 8.50M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 44.39M | 54.37M | 42.03M | 17.69M |
| Operating Income | - | -44.39M | -54.37M | -42.03M | -9.19M |
| EBITDA | - | -239.94M | -171.77M | -53.06M | -10.62M |
| Interest Expense | - | 93.00K | 150.00K | 179.00K | 65.00K |
| Pretax Income | - | -240.81M | -172.59M | -53.60M | -10.94M |
| Tax Provision | - | 1.00K | 10.00K | 259.00K | 3.00K |
| Net Income | - | -240.81M | -172.60M | -53.86M | -10.94M |
| Diluted EPS | -1.18 | -2.99 | -231.99 | -52.80 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 76.47M | 55.39M | 13.10M | 6.71M |
| Current Assets | - | 55.79M | 39.92M | 10.27M | 6.05M |
| Cash & Equivalents | - | 32.67M | 32.06M | 9.77M | 3.28M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | 0 | 2.31M |
| Total Liabilities | - | 524.60M | 14.15M | 8.23M | 9.90M |
| Current Liabilities | - | 12.36M | 13.56M | 7.40M | 6.33M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 991.00K | 4.66M | 966.00K | 643.00K |
| Total Equity | - | -448.12M | 41.23M | 4.86M | -3.19M |
| Shares Outstanding | - | 80.45M | 894.96K | 1.10M | 2.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -42.82M | -43.21M | -28.74M | -10.37M |
| Investing Cash Flow | - | 29.05M | 21.36M | 5.98M | 218.00K |
| Financing Cash Flow | - | -294.00K | 21.23M | 468.00K | 3.68M |
| Capital Expenditure | -7.55M | -367.00K | -6.00K | -24.00K | - |
| Free Cash Flow | - | -43.19M | -43.22M | -28.77M | -10.37M |
| Net Change in Cash | - | -14.06M | -619.00K | -22.29M | -6.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -108.2% |
| Net Margin % | - | - | - | - | -128.7% |
| ROE % | - | 53.7% | -418.6% | -1,107.3% | 343.1% |
| ROCE % | - | -69.2% | -130.0% | -737.6% | -2,369.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APLM
Apollomics Inc. (APLM) director discloses grant of 500 restricted stock units - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUjlaZGdxWWE5aEprb1psVmtUeDA2djhfVDdGWS12NzNjc2t5T3N5LUFEZVRqd0JHcEdvcHY1ZTNLMTRFV0hwVjMtXy0tVUFibGh6eDAxRHAyTzdtb2paMGEtQUI2LW11c2U4cHZKb3NIdWczV3kxc3NZY2xvdzRSSU9xem9rcGExMUpQcE…
Discipline and Rules-Based Execution in APLM Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQRnF4RnlyR3o1VDZKMkswcnNJbHVQSEx5U1FyT0ZKOHNtQlQ3MG13dm9vckNNNVJRMnU0dU4zX184S1lpbnR0V3gyTDYwQzRqT2ZpMlNvdXgtYnZQX2ZjWS1aTkNXNFFCTTR5cXhSTlhxamdIdzdYd0REdFlwYVdvbGFFbjRYU1RVUnd0MW…
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxOWGFZWmNlVTFWY3N5UWFjSjd5ZlVXWFZVTi1HOE9KcEtiNUlRYXM2dFlEREx1S1VYVDA4ZXNoUHltem5fbW5aOGdpelM5ZUY1MnJYeU5JaWNSVEFoN2stSTVhLUFlVF90dXBicUxZS09NbWZXUHNtc1hQZ1F5djA1SWlRajFUdmRqVXJsTm…
Apollomics Inc (APLM) Income Statement - TradingKey
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE56WXpSbUdwcDNlSld1MjVpMmRVcXlEOXp5aV8zOVBsdjFfZnMtdVpfT1NacDhjOFNhZ0U5ZGhlbFpSdUlHNm8taXdLek9mYWx5TzAyLUJiVVYwRDk1U092NU1wVThyRE52eXJob3ZWZ1o?oc=5" target="_blank">Apollomics Inc (…
Apollomics Inc. (APLM) appoints Hung-Hsien Yen to board - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQc1pxd2x4cnBvN2NveURRbmF4LTRLNGp1QjRJZ0xKZUVfdDc1aTJ5c0VyQzRvVFZzUnYxeUJfMmNFZHVTNmxBbHY4Y25jRlRtUnNZWkVTZkxiSl9sSEROeFpSUGswdHVnQlVMU3d2d2l6cUVrMDJHWUsyUWVYYkk1a05BSi1VblhfUUVBMT…
Apollomics Inc. (APLM) Faces Mild Pullback Amid Key Support Test - Ichimoku Cloud - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVUFLVFh2Y1dNdW5XcXJhU3c0QV8zRm1zVDFOdnVZX21lTFZQVWRUU3FINmdOT1owb3VzR2xvSy00cXY0ZzdDY1NRSU5OdXlWN1FjRS1BMm0wZUhSU0JadkY0c2Jod1ZBcWFqTlA4SGxfalp2Ynpxd3VMa2I3WXRXT1REN2QwOTVZcW5xU3…
APLM — Frequently Asked Questions
What is the current share price of Apollomics, Inc. (APLM)?
As of 2026-08-05 17:25 PDT, Apollomics, Inc. (APLM) trades at $17.28 on NasdaqCM. Its 52-week range is $3.93 to $36.65.
What is the market capitalisation of APLM?
Apollomics, Inc. (APLM) has a market capitalisation of $37.95M on NasdaqCM.
What is the P/E ratio of APLM?
APLM trades at a trailing price-to-earnings (P/E) ratio of -2.28. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is -11.64.
Is APLM a good stock to buy?
This page provides a data-driven analysis of Apollomics, Inc. (APLM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.